REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

09/09/2020 15:15

RNS Number : 5214Y
  
GlaxoSmithKline PLC
  
09 September 2020
  
 

GlaxoSmithKline plc (the 'Company')
Transaction notification
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels 




b)


Position/status


President, Global Pharmaceuticals




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Following the vesting on 4 September 2020 of 25% of an award made on 14 February 2018 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Miels will receive a cash payment of £373,151.97 less applicable tax withholding in respect of 25,999.998 notional Ordinary Shares. 




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£14.352


25,999.998


 




 


 


 


 




d)


Aggregated information
 
 


N/A (single transaction) 




Aggregated volume Price


 




e)


Date of the transaction


2020-09-04




f)


Place of the transaction
 


N/A




 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHZKLFBBKLFBBB